Type I Diabetes Clinical Trial
Official title:
Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)
Verified date | October 30, 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Type 1 diabetes (T1D) is a common chronic disease in children, occurring in
approximately 1 of every 400 to 600 children. Children with T1D are unable to produce
insulin, a hormone that allows the body to use glucose from food. Children with T1D
manage their diabetes by taking insulin, monitoring their blood glucose levels, and
watching their diet, including carbohydrates.
- Carbohydrates come from many different kinds of food, and recent research has shown that
different foods have a different effect on the level of glucose in the blood. In
general, whole, unprocessed foods (e.g., fruits, vegetables, whole grains, legumes) have
a lower glycemic index (GI), which means that they cause smaller, more sustained blood
sugar levels. Additionally, these foods are rich in nutrients. Nutrient-poor
carbohydrates come from foods made with refined grains and sugars, such as breads,
crackers, and breakfast cereals; they general cause a more rapid increases in blood
sugar (i.e., a high GI). Lower GI diets may help people with T1D manage their blood
glucose levels more easily.
Objectives:
- To determine the utility of a whole foods, low GI diet in the management of T1D.
- To determine the utility of a behavioral intervention to promote healthful family
dietary behaviors, including eating more fruits, vegetables, whole grains, and legumes,
and fewer refined carbohydrates.
- To determine how the dietary intervention affects quality of life, satisfaction with the
diet, and risk for problem eating behaviors.
Eligibility:
- Children 8 to 16 years of age who have been diagnosed with T1D for more than 12 months, and
who use insulin injections to maintain normal blood glucose levels.
Design:
- Families will be divided into two groups: an intervention group that will participate in
intensive dietary intervention and continuous glucose monitoring (CGM) and a control
group that will not have the dietary intervention but will have CGM and scheduled
contacts with study staff.
- Intervention group families will have 11 family-based and 2 group-based sessions
consisting of behavioral techniques and educational content about eating nutrient-dense,
low GI foods. CGM results will give families feedback about how their diet affects blood
glucose levels. At least one parent and the child with T1D will participate in the
intervention.
- Intervention topics will consist of goal setting, behavior self-monitoring, educational
information, and problem solving, among others. Parents and children will record the
foods they eat.
- Control group families will participate in 11 family-based sessions consisting of CGM
feedback.
- Assessments will be conducted at 6, 12, and 18 months, and medical record information,
including blood and urine testing, will be obtained at each routine clinic visit.
Status | Completed |
Enrollment | 293 |
Est. completion date | November 27, 2013 |
Est. primary completion date | November 27, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 17 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Child age 8.0-16.9 years 2. T1D: classical presentation and/or antibody positivity 3. Diabetes duration greater than or equal to 12 months 4. Daily insulin dose greater than or equal to 0.5 units/kilogram 5. Hemoglobin A1c greater than or equal to 7.0% and less than or equal to 9.5% 6. Insulin regimen - a. Greater than or equal to 3 injections daily, OR - b. Continuous subcutaneous insulin infusion (insulin pump) (CSII) 7. Blood glucose monitoring frequency: Greater than or equal to 3 checks daily 8. Stable living situation (guardian and address) for greater than or equal to 6 months 9. Joslin Clinic attendance - a. At least one Joslin Clinic visit in last year, AND - b. Anticipated care at Joslin Clinic for duration of study EXCLUSION CRITERIA: 1. Daily use of premixed insulin 2. Transition to CSII (insulin pump) therapy in last 3 months 3. Continuous glucose monitoring use in last 3 months 4. Participation in a different intervention study in the last 6 months 5. Presence of co-morbid conditions (any of the following): - a. Celiac disease, inflammatory bowel disease, or other significant gastrointestinal condition - b. Systemic glucocorticoid use (cumulative 1 month during last year) - c. Significant multiple food allergies - d. Significant mental illness defined by either: - 1. Major psychiatric disorder (e.g., eating disorder, major psychoses), OR - 2. Inpatient psychiatric admission during last 6 months 6. Significant medical or psychiatric illness in caregiver that would prevent active participation in the study 7. Intent to enroll in another intervention study during the course of this study |
Country | Name | City | State |
---|---|---|---|
United States | Joslin Diabetes Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2007 Jan;30 Suppl 1:S48-65. — View Citation
Anderson BJ, Auslander WF, Jung KC, Miller JP, Santiago JV. Assessing family sharing of diabetes responsibilities. J Pediatr Psychol. 1990 Aug;15(4):477-92. — View Citation
Anderson EJ, Richardson M, Castle G, Cercone S, Delahanty L, Lyon R, Mueller D, Snetselaar L. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc. 1993 Jul;93(7):768-72. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in glycemic control, change in dietary intake | 18 months | ||
Secondary | Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05160142 -
Diabetes Inspired Culinary Education
|
Early Phase 1 | |
Withdrawn |
NCT05035368 -
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01928329 -
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
|
Phase 2 | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT04279613 -
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
|
Phase 1 | |
Not yet recruiting |
NCT02117518 -
Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients
|
N/A | |
Withdrawn |
NCT01477476 -
Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
|
Phase 2 | |
Terminated |
NCT01308437 -
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
|
Phase 3 | |
Terminated |
NCT01652911 -
A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT06242548 -
How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude
|
N/A | |
Completed |
NCT00351650 -
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
|
N/A | |
Withdrawn |
NCT00361608 -
Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device
|
N/A | |
Terminated |
NCT03653533 -
Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump
|
N/A | |
Completed |
NCT00340639 -
Management of Type 1 Diabetes Among Adolescents
|
N/A | |
Completed |
NCT02002130 -
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
|
Phase 1 | |
Completed |
NCT02634216 -
Effects of Capros in Patients With Type-1 Diabetes
|
N/A | |
Withdrawn |
NCT01623388 -
Epigenetic Modifications of Diabetes Mellitus Type I
|
N/A | |
Completed |
NCT02612493 -
Obesity and Metabolic Surgery in Patients With Type I Diabetes
|
N/A | |
Completed |
NCT01843114 -
Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects
|
N/A | |
Withdrawn |
NCT01398670 -
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics
|
Phase 3 |